

21 | 05 | 2024

FATIMA **SALIH**, BETSY WONDERLY **TRAINOR**, ISABELLE **TONGIO**, DALIA **DAWOUD**

REPORT of the Regulatory/HTA/Payer EAP

Session 8

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.





UNIVERSITÀ
di VERONA



University Medical Center Groningen



RAMBAM
Health Care Campus



**UNIVERSIDAD
DE LA RIOJA**



NICE National Institute for
Health and Care Excellence

Gesundheit Österreich
GmbH



Eighth EAP session

1.1. Meeting overview

The eighth session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on 21 May 2024. There were eight members of the EAP in attendance.

1.2. Topics and themes discussed

1. VALUE-Dx Progress update:
 - Update of next steps for the project.
2. Overview of key project outputs.
3. Framing of project outputs to policymakers.
4. Sustainability of VALUE-Dx outputs and their useability beyond the project timeline.

